Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dicyclomine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.95 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.95 |
| ▸ | TSHR | P16473 | 4/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.95 |
| ▸ | DRD1 | P21728 | 2/20 | 0.95 |
| ▸ | DRD3 | P35462 | 2/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | HRH2 | P25021 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicyclomine SCHEMBL3317 | 0.97 | CYP3A4 (1.00) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL20536388 | 0.96 | CYP3A4 (1.00) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL41670 | 0.96 | CYP3A4 (1.00) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL14322178 | 0.96 | CYP3A4 (0.97) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL10684080 | 0.96 | CYP3A4 (0.97) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL5501641 | 0.96 | CYP3A4 (1.00) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL7023518 | 0.95 | CYP3A4 (0.97) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL6285092 | 0.93 | CYP3A4 (0.95) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL2481238 | 0.92 | CYP3A4 (0.90) | CYP3A4CHRM2CHRM1LMNACYP1A2 | |
| Dicyclomine SCHEMBL8082728 | 0.91 | CYP3A4 (0.90) | CYP3A4CHRM2CHRM1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20220334101-A1 | MODULATING EXTRACELLULAR MATRIX MOVEMENT | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-10-20 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CHRM1 1604/4885CHRM3 1038/4885CYP3A4 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.